The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

12 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.EBI
Zhejiang Hisun Pharmaceutical
PYRIDONE COMPOUNDS AS TRPA1 INHIBITORSBDB
D. E. Shaw Research
In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitorsBDB
University of Virginia Patent Foundation
SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAMEBDB
Arbutus Biopharma
Compounds for the modulation of cyclophilins functionBDB
The University Court of The University of Edinburgh
Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonistBDB
Suven Life Sciences
Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of useBDB
Dana-Farber Cancer Institute
Substituted pyrimidines for preventing or treating cancer and inflammatory diseasesBDB
Korea Research Institute of Chemical Technology
The different inhibition mechanisms of OXA-1 and OXA-24 ß-lactamases are determined by the stability of active site carboxylated lysine.BDB
Case Western Reserve University
Heterocyclic derivatives and their use in the treatment of neurological disordersBDB
Novartis
Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin.BDB
Stanford University